Aalto Bio Reagents Ltd.-Biosynth

Aalto Bio Reagents has moved the ongoing content from this LinkedIn channel to Biosynth's LinkedIn page please follow us there. https://lnkd.in/gMgfu-YZ

We are thrilled to announce that Aalto Bio Reagents has been named "Exporter of the Year" in the Life Sciences industry at the Irish Exporters Association Export Industry Awards 2023 This award is a testament to our team's dedication and our commitment to providing top-quality products to customers worldwide. Thanks to our incredible customers and partners for their trust and support. This recognition inspires us to keep pushing boundaries in the life sciences field. #lifescience #ivdindustry #invitrodiagnistics #exporter #exportawards2023

Following the outbreak of the Nipah virus in India. The Indian authorities have instituted a mass testing for the deadly virus that has killed two people in Kerela. We have developed a monoclonal antibody to screen and detect the virus. This MAb can help detect, monitor and treat the disease at source. If you are a scientist or a researcher looking at this virus please feel free to reach out to us at biologics@biosynth.com and we'll be happy to help. We also hope that everyone's safe and healthy!

We are excited to share that we have seen an increased interest in our Human Hybrid IgM Monoclonal antibody range. We look forward to keep innovating and creating products that help boost development. Click on the link below for further details regarding our antibody range or email dub.sales@biosynth.com for further information. https://rb.gy/3etpd #diseasestateplasma #biosynth #antibodies #monoclonalantibodies #plasma #plasmashortage #IgM #creativesolutions #innovation

We are pleased to announce that Aalto Bio Reagents are rebranding to Biosynth as of today. We are excited to fully join Biosynth, offering one of the widest selections of antibodies, antigens and other biological reagents for research, development, and diagnostics along with more than a million other products. We have collected some of the frequently asked questions related to our rebrand on August 1st, 2023, to ensure a smooth transition. https://lnkd.in/ej7bAcY8 It is important to note that there will be no changes to:  •The form, fit, and function of any of our products. •The product catalogue numbers. •The manufacturing locations, processes, or other elements that impact product quality. • Your account manager and support representatives.   #Biosynth #Rebranding 

The Aalto Bio Reagents (Biosynth Group) team has arrived at AACC 2023 and are eagerly waiting to meet all those attending. We hope everyone has a successful week ahead! Please visit our website at https://lnkd.in/ekNc5Kes to view our products. Contact us at info@aaaltobioreagents.com for further details or for setting up a meeting with us. #aacc2023 #aacc #biosynth #biologicalproducts #antibodies #antigens #plasma #biospecimens #veterinary

We are excited to share that we will be exhibiting at AACC 2023 from 23rd of July - 27th of July 2023. Please visit us at booth 4224 and we are looking forward to seeing everyone attending. We are delighted to offer a range of novel human hybrid IgM monoclonal antibodies for CMV, HSV-1/2, Measles, Mumps, Mycoplasma pneumoniae, Rubella, Toxoplasma gondii and VZV. These are intended to replace hard to find disease state IgM positive human plasma, are produced in mice genetically modified to express human IgM heavy chain constant region. They are then concentrated and spiked into an IgG depleted and delipidised human serum matrix which ensures that the final product is as close as possible to the natural disease state IgM positive human plasma. Testing in both ELISA and bead-based applications shows the products behave in an almost identical manner as the natural source. If you would like to further discuss this product, please visit our website at https://rb.gy/dtsnp or contact us at info@aaltobioreagents.com to meet our commercial team. #aacc2023 #aacc #biorawmaterials #biosupply #plasma #anitbody #monoclonalantibodies